p63 and p73: old members of a new family.

[1]  W. Kaelin.  The p53 gene family , 1999, Oncogene.

[2]  J. Roth,et al.  Failure of viral oncoproteins to target the p53-homologue p51A. , 1999, The Journal of general virology.

[3]  Michael Bamshad,et al.  Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome , 1999, Cell.

[4]  H. Yokozaki,et al.  Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype , 1999, International journal of cancer.

[5]  Makoto Hijikata,et al.  New p73 variants with altered C-terminal structures have varied transcriptional activities , 1999, Oncogene.

[6]  M. Tschan,et al.  Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. , 1999, Cancer research.

[7]  C. Arrowsmith,et al.  Solution structure of a conserved C‐terminal domain of p73 with structural homology to the SAM domain , 1999, The EMBO journal.

[8]  A. Harris,et al.  MDM2 and MDMX bind and stabilize the p53-related protein p73 , 1999, Current Biology.

[9]  C. Garbe,et al.  Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines , 1999, International journal of cancer.

[10]  C. Bartram,et al.  Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. , 1999, Blood.

[11]  N. L. Thangue,et al.  Promoter specificity and stability control of the p53-related protein p73 , 1999, Oncogene.

[12]  J. Herman,et al.  Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. , 1999, Cancer research.

[13]  K. Vousden,et al.  Mdm2 binds p73α without targeting degradation , 1999, Oncogene.

[14]  B. Clurman,et al.  P73 mutations and expression in adult de novo acute myelogenous leukemia , 1999, Leukemia.

[15]  U. Moll,et al.  Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. , 1999, Cancer research.

[16]  Y. Ishikawa,et al.  The expression of p73 is increased in lung cancer, independent of p53 gene alteration , 1999, British Journal of Cancer.

[17]  T. Davison,et al.  p73 and p63 Are Homotetramers Capable of Weak Heterotypic Interactions with Each Other but Not with p53* , 1999, The Journal of Biological Chemistry.

[18]  Jijie Gu,et al.  p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage , 1999, Nature.

[19]  S. Kato,et al.  Mutational analysis of p51A/TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer , 1999, Oncogene.

[20]  Yohko Nakamura,et al.  Mutational analysis of the p73 Gene in human breast cancers , 1999, International journal of cancer.

[21]  S. Chi,et al.  Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer. , 1999, Cancer research.

[22]  G Melino,et al.  Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ , 1999, Cell Death and Differentiation.

[23]  W. Kaelin,et al.  MDM2 Suppresses p73 Function without Promoting p73 Degradation , 1999, Molecular and Cellular Biology.

[24]  E. Salido,et al.  Mouse p73 gene maps to the distal part of chromosome 4 and might be involved in the progression of gamma-radiation-induced T-cell lymphomas. , 1999, Cancer research.

[25]  C. L. Cunsolo,et al.  Different p73 splicing variants are expressed in distinct tumour areas of a multifocal neuroblastoma , 1999, Cell Death and Differentiation.

[26]  D. Tindall,et al.  Mutation and expression analysis of the p73 gene in prostate cancer , 1999, The Prostate.

[27]  A. Jochemsen,et al.  Distinct Regulation of p53 and p73 Activity by Adenovirus E1A, E1B, and E4orf6 Proteins , 1999, Molecular and Cellular Biology.

[28]  Christopher P. Crum,et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.

[29]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[30]  J. Roth,et al.  Inactivation of the p53-homologue p73 by the mdm2-oncoprotein , 1999, Oncogene.

[31]  G. Wahl,et al.  A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking , 1999, The EMBO journal.

[32]  D. Tindall,et al.  Overexpression of the wild type p73 gene in human bladder cancer , 1999, Oncogene.

[33]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[34]  F. McKeon,et al.  p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent , 1999, Oncogene.

[35]  A. Nakagawara,et al.  Absence of mutation of the p73 gene localized at chromosome 1p36.3 in hepatocellular carcinoma , 1999, British Journal of Cancer.

[36]  J. Roth,et al.  The large T antigen of simian virus 40 binds and inactivates p53 but not p73. , 1998, The Journal of general virology.

[37]  Xinbin Chen,et al.  The potential tumor suppressor p73 differentially regulates cellular p53 target genes. , 1998, Cancer research.

[38]  N. Nomura,et al.  p73, a geme related to p53, is not mutated in esophageal carcinomas , 1998, International journal of cancer.

[39]  G. Melino,et al.  Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity , 1998, Journal of Experimental Medicine.

[40]  W. Kaelin,et al.  Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73 , 1998, Molecular and Cellular Biology.

[41]  S. Swendeman,et al.  Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[42]  J. Roth,et al.  Inactivation of p53 but Not p73 by Adenovirus Type 5 E1B 55-Kilodalton and E4 34-Kilodalton Oncoproteins , 1998, Journal of Virology.

[43]  D. Livingston,et al.  p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.

[44]  David I. Smith,et al.  Loss of imprinting and allele switching of p73 in renal cell carcinoma , 1998, Oncogene.

[45]  C. Sherr,et al.  Tumor surveillance via the ARF-p53 pathway. , 1998, Genes & development.

[46]  M. Kubbutat,et al.  Regulation of Mdm2-Directed Degradation by the C Terminus of p53 , 1998, Molecular and Cellular Biology.

[47]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[48]  W. Liu,et al.  Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. , 1998, Genomics.

[49]  H. Kato,et al.  A second p53-related protein, p73L, with high homology to p73. , 1998, Biochemical and biophysical research communications.

[50]  J. Jen,et al.  A new human p53 homologue , 1998, Nature Medicine.

[51]  Chikashi Ishioka,et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.

[52]  D. Tindall,et al.  Activation of p73 silent allele in lung cancer. , 1998, Cancer research.

[53]  S. Nomoto,et al.  Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. , 1998, Cancer research.

[54]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[55]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[56]  C. Bamberger,et al.  A novel protein with strong homology to the tumor suppressor p53 , 1997, Oncogene.

[57]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[58]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[59]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[60]  Se-Jin Lee,et al.  Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member , 1997, nature.

[61]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution: a second look. , 1996, Journal of molecular biology.

[62]  W. Deppert,et al.  Negative feedback regulation of wild‐type p53 biosynthesis. , 1995 .

[63]  A. Levine,et al.  The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[64]  A. Levine,et al.  Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids , 1995, Molecular and cellular biology.

[65]  M. Schwab,et al.  There may be two tumor suppressor genes on chromosome arm Ip closely associated with biologically distinct subtypes of neuroblastoma , 1994, Genes, chromosomes & cancer.

[66]  M. Kulesz-Martin,et al.  Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells , 1994, Molecular and cellular biology.

[67]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[68]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[69]  T. Crook,et al.  Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53‐mediated repression of transcription. , 1992, The EMBO journal.

[70]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[71]  A. Berk,et al.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein , 1992, Nature.

[72]  M. Kulesz-Martin,et al.  Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. , 1992, Nucleic acids research.

[73]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[74]  Wolf,et al.  Immunologically distinct p53 molecules generated by alternative splicing , 1986, Molecular and cellular biology.

[75]  A. Levine,et al.  Adenovirus early region 1B 58,000-dalton tumor antigen is physically associated with an early region 4 25,000-dalton protein in productively infected cells , 1984, Journal of virology.

[76]  G. Attardi,et al.  Synthesis and turnover of mitochondrial ribonucleic acid in HeLa cells: the mature ribosomal and messenger ribonucleic acid species are metabolically unstable , 1981, Molecular and cellular biology.

[77]  A. Levine,et al.  Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells , 1981, Molecular and cellular biology.

[78]  A. Levine,et al.  Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.

[79]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[80]  J U Bowie,et al.  p53 Family members p63 and p73 are SAM domain‐containing proteins , 1999, Protein science : a publication of the Protein Society.

[81]  F. Haluska,et al.  Mutational and expression analysis of the p73 gene in melanoma cell lines. , 1999, Cancer research.

[82]  P. Bork,et al.  Predicting functions from protein sequences—where are the bottlenecks? , 1998, Nature Genetics.